VC: Cerenis garners $53.5M in second round

Cerenis garners $53.5M in second round

VENTURE CAPITAL
COMPANY	AMOUNT/ROUND	LEAD INVESTORS	DESCRIPTION
Cerenis Therapeutics [1] Ann Arbor, MI and Toulouse, France	$53.5M Second	TVM Capital	Cerenis says much of the money will be used to back the development of its lead compound, Cerenis HDL, a synthetic form of HDL that mimics natural HDL.
EyeGate Pharma [2] Waltham, MA	$10M Second	Innoven Partenaires and Ventech	EyeGate is researching new drug/device therapies for macular degeneration and other eye diseases.
Yaupon Therapeutics [3] Radnor, PA	$4M Second	Osage Ventures	The financing will support the continued development of Yaupon's multiple clinical programs targeting diverse medical needs in the treatment of lymphoma, addiction and neuropathic pain.